Tags

Type your tag names separated by a space and hit enter

Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Jpn J Clin Oncol. 2012 Jun; 42(6):471-6.JJ

Abstract

OBJECTIVE

To analyze the clinicopathological features and prognosis of T1mic, a, bN0M0 breast cancer.

METHODS

The clinical data and survival status of 4487 cases of operable breast cancer treated in our hospital from 2002 to 2005 were collected, including 372 cases with T1mic, a, bN0M0 breast cancers. These patients were divided into four subtypes: Luminal A, Luminal B, triple-negative and human epidermal growth factor receptor 2-positive. Disease-free survival and risk factors for recurrence were identified.

RESULTS

We identified 372 eligible patients. The median follow-up was 78 months (range: 5-106 months). Univariate analysis showed age, adjuvant endocrine therapy, hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. Multivariate analysis showed that hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. In the hormonal receptor-positive group, human epidermal growth factor receptor 2-positive patients (Luminal B) had a four times higher recurrence risk than human epidermal growth factor receptor 2 negative (Luminal A) patients. However, there was no statistically significant difference between hormonal receptor-negative groups (triple-negative and human epidermal growth factor receptor 2-positive).

CONCLUSIONS

Hormonal receptor and human epidermal growth factor receptor 2 were independent factors of 5-year disease-free survival for patients with T1mic, a, bN0M0 breast cancer. The Luminal B group had a worse prognosis than the Luminal A group, but there was no statistically significant difference between triple-negative and human epidermal growth factor receptor 2-positive groups.

Authors+Show Affiliations

Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, China. tonghang@medmail.com.cnNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22493058

Citation

Li, Junnan, et al. "Clinical Features and Survival Analysis of T1mic, A, bN0M0 Breast Cancer." Japanese Journal of Clinical Oncology, vol. 42, no. 6, 2012, pp. 471-6.
Li J, Liu X, Tong Z. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. Jpn J Clin Oncol. 2012;42(6):471-6.
Li, J., Liu, X., & Tong, Z. (2012). Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. Japanese Journal of Clinical Oncology, 42(6), 471-6. https://doi.org/10.1093/jjco/hys046
Li J, Liu X, Tong Z. Clinical Features and Survival Analysis of T1mic, A, bN0M0 Breast Cancer. Jpn J Clin Oncol. 2012;42(6):471-6. PubMed PMID: 22493058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. AU - Li,Junnan, AU - Liu,Xiaodong, AU - Tong,Zhongsheng, Y1 - 2012/04/03/ PY - 2012/4/12/entrez PY - 2012/4/12/pubmed PY - 2012/7/25/medline SP - 471 EP - 6 JF - Japanese journal of clinical oncology JO - Jpn J Clin Oncol VL - 42 IS - 6 N2 - OBJECTIVE: To analyze the clinicopathological features and prognosis of T1mic, a, bN0M0 breast cancer. METHODS: The clinical data and survival status of 4487 cases of operable breast cancer treated in our hospital from 2002 to 2005 were collected, including 372 cases with T1mic, a, bN0M0 breast cancers. These patients were divided into four subtypes: Luminal A, Luminal B, triple-negative and human epidermal growth factor receptor 2-positive. Disease-free survival and risk factors for recurrence were identified. RESULTS: We identified 372 eligible patients. The median follow-up was 78 months (range: 5-106 months). Univariate analysis showed age, adjuvant endocrine therapy, hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. Multivariate analysis showed that hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. In the hormonal receptor-positive group, human epidermal growth factor receptor 2-positive patients (Luminal B) had a four times higher recurrence risk than human epidermal growth factor receptor 2 negative (Luminal A) patients. However, there was no statistically significant difference between hormonal receptor-negative groups (triple-negative and human epidermal growth factor receptor 2-positive). CONCLUSIONS: Hormonal receptor and human epidermal growth factor receptor 2 were independent factors of 5-year disease-free survival for patients with T1mic, a, bN0M0 breast cancer. The Luminal B group had a worse prognosis than the Luminal A group, but there was no statistically significant difference between triple-negative and human epidermal growth factor receptor 2-positive groups. SN - 1465-3621 UR - https://www.unboundmedicine.com/medline/citation/22493058/Clinical_features_and_survival_analysis_of_T1mic_a_bN0M0_breast_cancer_ L2 - https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hys046 DB - PRIME DP - Unbound Medicine ER -